| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/21/2006 | US20060287245 Anti-tumor agents |
| 12/21/2006 | US20060287244 L-Threonine derivatives of high therapeutic index |
| 12/21/2006 | US20060287241 Combination comprising N-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate |
| 12/21/2006 | US20060287238 Treating a gram negative bacterial infection with a synergistic mixture of a DnaK inhibitor such as pyrrhocoricin or drosocin and another bactericide such as fluoroquinolone, beta-lactam, tetracycline, macrolide, aminoglycoside, glycopeptide, or folic acid synthesis inhibitor family of antibiotics. |
| 12/21/2006 | US20060287227 Gonadal function improving agents |
| 12/21/2006 | US20060287225 injecting an alpha-v. beta 3 or alpha-v, beta 5 inhibitor into the vitreous body of the eye; angiogenesis inhibition; diabetic retinopathy, macular degeneration, myopia, ocular histoplasmosis; (2S)-2-benzyloxycarboxamido-3-(2-guanidinomethyl-1,4-benzodioxan-6-yl)propionic acid |
| 12/21/2006 | US20060287220 Water soluble paclitaxel prodrugs |
| 12/21/2006 | US20060286622 Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| 12/21/2006 | US20060286614 Monitoring effective thrombin levels in patients undergoing anticoagulant therapy; measuring circulating levels of soluble endothelial protein C receptor (sEPCR) |
| 12/21/2006 | US20060286574 Compositions and methods for enhancing drug sensitivity and treating drug resistant infections and diseases |
| 12/21/2006 | US20060286567 Salicylamide-lanthanide complexes for use as luminescent markers |
| 12/21/2006 | US20060286556 Autoimmune encephalomyelitis; multiple sclerosis; antagonize or inhibit CXCL13 |
| 12/21/2006 | US20060286265 Food composition comprising a satiety enhancing amount of triacylglycerol and use in the manufature of a medicament for the treatment or prevention of obesity |
| 12/21/2006 | US20060286187 Natural lycopene concentrate and method for production thereof |
| 12/21/2006 | US20060286186 Method and means for improving bowel health |
| 12/21/2006 | US20060286185 Veterinary composition and method of using same |
| 12/21/2006 | US20060286183 Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being |
| 12/21/2006 | US20060286182 Synergistic cinnamon combinations and methods for enhancing insulin activity |
| 12/21/2006 | US20060286181 Diet supplements for causing fast weight loss, improving daytime energy, promoting nighttime relaxation and sleep, controlling appetite and/or increasing metabolism |
| 12/21/2006 | US20060286177 coadministering bufexamac and a corticosteroid such as prednisolone; autoimmune disorders; side effect reduction |
| 12/21/2006 | US20060286174 non-coated complex particulate comprising ion consisting of a styrene-divinylbenzene sulfonic acid cationic exchange resin and a pharmaceutically active material such as oxycodone hydrochloride, tramadol hydrochloride complexed with ion exchange resin; avoids use of coatings and large amounts of solvents |
| 12/21/2006 | US20060286173 Drug delivery system for sub-tenon s capsule adminstration of fine grains |
| 12/21/2006 | US20060286171 Bone morphogenetic protein formulations |
| 12/21/2006 | US20060286170 Method and composition for treating cancer using cellular organelle crystallizing agents |
| 12/21/2006 | US20060286168 Process for producing coated preparation |
| 12/21/2006 | US20060286167 Compositions and methods for the treatment of neurodegenerative diseases |
| 12/21/2006 | US20060286166 90% of the particles have a particle size of less than about 40 microns; have profound effects on the ease and reproducibility of formulation |
| 12/21/2006 | US20060286164 Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same |
| 12/21/2006 | US20060286163 Pharmaceutical composition of topiramate |
| 12/21/2006 | US20060286161 Injectable liposomal depots for delivering active ingredients |
| 12/21/2006 | US20060286159 Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect |
| 12/21/2006 | US20060286158 Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents |
| 12/21/2006 | US20060286157 Protein mixtures for wound healing |
| 12/21/2006 | US20060286153 Anti-viral lotion tissue and methods for making and using the same |
| 12/21/2006 | US20060286150 Prevent menopause syndrome; therapy for skin aging; topical applying |
| 12/21/2006 | US20060286149 Low molecular weight polyglucosamines and polygalactosamines |
| 12/21/2006 | US20060286146 Hemostatic compositons and methods |
| 12/21/2006 | US20060286140 Implants with attached silylated therapeutic agents |
| 12/21/2006 | US20060286123 Porcine Respiratory Reproductive Syndrome (PRRS); viral disease affecting pigs |
| 12/21/2006 | US20060286110 Bax-responsive genes for drug target identification in yeast and fungi |
| 12/21/2006 | US20060286108 Topical compositions for the treatment of chronic wounds |
| 12/21/2006 | US20060286106 determining total protein bound or total free levels or both of one or more myeloperoxidase (MPO)-generated amino acids in a bodily sample of blood, serum, plasma, or urine from the patient |
| 12/21/2006 | US20060286105 Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency |
| 12/21/2006 | US20060286088 Administration of enoxaparin sodium to patients 75 years and older with ST-segment elevation myocardial infarction |
| 12/21/2006 | US20060286073 COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ANGIOGENESIS |
| 12/21/2006 | US20060286065 Useful in extending the in vivo circulating life of biologically active materials; bicine linker allows for the manipulation of the hydrolysis rate of the prodrug, thereby releasing the native entities at various rates in vivo as well as in vitro |
| 12/21/2006 | US20060286064 Based on biodegradable polymers containing polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) and immunostimulatory adjuvants; for delivery of compositions that bind to major histocompatibility complexes (MHC) alleles |
| 12/21/2006 | US20060286063 Glycoprotein IIb/IIa (GPIIb/IIIa) inhibitor such as xemilofiban and rapamycin attached to a polymer such as a polyamideester copolymer of leucine, lysine, sebacic acid and hexanediol |
| 12/21/2006 | US20060286054 Pharmaceutical compositions for the treatment of psoriasis |
| 12/21/2006 | US20060286045 microbiologically stable consumer product such as food or beverage containing oil and water comprising a preservative system of aliphatic isothiocyanate and aromatic isothiocyanate ( allyl isothiocyanate and 4-hydroxybenzyl isothiocyanate); storage stability |
| 12/21/2006 | US20060286043 Delivery of antihistamines through an inhalation route |
| 12/21/2006 | US20060286042 Condensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone |
| 12/21/2006 | US20060286041 Mrp iv inhibitors for the treatment of respiratory diseases |
| 12/21/2006 | US20060286040 Medicament compositions comprising a heterocyclic compound and an anticholinergic |
| 12/21/2006 | US20060286039 Novel treatment for pathological aggression |
| 12/21/2006 | US20060286038 Pulmonary surfactant formulations |
| 12/21/2006 | US20060286037 Heart-slowing drug containing short-acting ß blocker as the active ingredient |
| 12/21/2006 | US20060286033 Targeting pulmonary epithelium using ADRP |
| 12/21/2006 | US20060286032 A radiosotope-chitosan complex for treatment of prostate cancer |
| 12/21/2006 | US20060286031 Modulators of tissue regeneration |
| 12/21/2006 | US20060286030 an antigen binding fragment comprising a heavy chain and a light chain variable region amino acid sequences, associated to effector cells for triggering antibody-dependent cell-mediated cytotoxicity (ADCC) mechanisms; useful for inhibiting proliferation and/or killing melanoma cells |
| 12/21/2006 | DE19916460B4 Substituierte Benzimidazole, deren Herstellung und Anwendung Substituted benzimidazoles, their preparation and application |
| 12/21/2006 | DE19843489B4 Benzoylguanidin-Abkömmlinge mit vorteilhaften Eigenschaften, Verfahren zu ihrer Herstellung und ihre Verwendung bei der Herstellung von Arzneimitteln, sowie diese enthaltende pharmazeutische Zubereitung Benzoylguanidine-derivatives having advantageous properties, to processes for their preparation and their use in the manufacture of medicinal products and pharmaceutical preparation containing them |
| 12/21/2006 | DE102005029382B3 New alkoxymethylyl substituted benzoic acid derivatives are peroxisome proliferation activated receptor agonists used for treating and/or preventing e.g. diabetes mellitus, dyslipidemia and disturbances in fatty acid metabolism |
| 12/21/2006 | DE102005027517A1 Verfahren zur Herstellung von Dihydrochinazolinen Process for the preparation of dihydroquinazolines |
| 12/21/2006 | DE102005026762A1 Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen Azolopyridin-2-one derivatives as inhibitors of lipases, and phospholipases |
| 12/21/2006 | DE102005018026B4 Substituierte Styrole, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer Substituted styrenes, processes for their preparation and their use as anti-inflammatories |
| 12/21/2006 | DE102005014141B4 Tablettenförmige Retardzubereitung gegen Schwindel Delayed-release tablets shaped against scams |
| 12/21/2006 | DE102004025071B4 Verfahren zur Herstellung von Diphenylazetidinon-Derivaten Process for the preparation of derivatives diphenylazetidinone |
| 12/21/2006 | CA2632375A1 Diclofenac formulations and methods of use |
| 12/21/2006 | CA2627589A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion |
| 12/21/2006 | CA2612413A1 Compounds for inhibition of 5-hydroxytryptamine and norepinephrine reuptake or for treatment of depression disorders, their preparation processes and uses thereof |
| 12/21/2006 | CA2612324A1 N-acyl derivatives of amino acids, a process for preparation thereof, a pharmaceutical composition and use thereof as antiallergic, anti-inflammatory and hypolipidemic agents |
| 12/21/2006 | CA2612299A1 Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists |
| 12/21/2006 | CA2612298A1 Anti-inflammatory agents |
| 12/21/2006 | CA2612288A1 Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
| 12/21/2006 | CA2612217A1 Anti-inflammatory agents |
| 12/21/2006 | CA2612200A1 Method of cancer treatment using sirna silencing |
| 12/21/2006 | CA2612081A1 2,5-bis-diamimne [1 , 4] benzoquinone-derivatives |
| 12/21/2006 | CA2612061A1 Stable cannabinoid compositions comprising crystalline trans-(±)-delta9-tetrahydrocannibinol |
| 12/21/2006 | CA2611979A1 Substituted arylpyrazoles |
| 12/21/2006 | CA2611935A1 Synergistic prebiotic compositions |
| 12/21/2006 | CA2611917A1 Injection |
| 12/21/2006 | CA2611911A1 Installation for guiding a gas for devices used to treat granular products by drying, film-coating or coating, especially an incoming air unit, and device comprising one such installation |
| 12/21/2006 | CA2611910A1 Anthranilic acid derivatives |
| 12/21/2006 | CA2611907A1 Mrp iv inhibitors for the treatment of respiratory diseases |
| 12/21/2006 | CA2611893A1 Tetrahydroquinolines for use as modulators of the mitotic motor protein eg5 |
| 12/21/2006 | CA2611892A1 Tetrahydroquinoline derivatives as motor protein eg5 inhibitors and antitumor agents |
| 12/21/2006 | CA2611883A1 Method for solubilizing metronidazole |
| 12/21/2006 | CA2611869A1 Pharmaceutical composition comprising an organopolysiloxane elastomer and a solubilized active principle |
| 12/21/2006 | CA2611865A1 N2-quinolyl or isoquinolyl substituted purine derivatives, the preparation and uses thereof |
| 12/21/2006 | CA2611831A1 A carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof |
| 12/21/2006 | CA2611796A1 Improved antimicrobial peroxidase compositions |
| 12/21/2006 | CA2611711A1 Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor |
| 12/21/2006 | CA2611680A1 Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
| 12/21/2006 | CA2611668A1 Formulation of a thienopyridine platelet aggregation inhibitor |
| 12/21/2006 | CA2611592A1 Liquid pharmaceutical formulations of docetaxel |
| 12/21/2006 | CA2611587A1 Thienopyrimidine and thienopyridine derivatives as flt-3 kinase inhibitors |
| 12/21/2006 | CA2611584A1 Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
| 12/21/2006 | CA2611562A1 Trisubstituted amines as phosphodiesterase 4 inhibitors |